Raju Prasad

Stock Analyst at William Blair

(n/a)

# 4,467

Out of 4,876 analysts

11

Total ratings

16.67%

Success rate

-47.19%

Average return

Main Sectors:

Top Industries:

Stocks Rated by Raju Prasad

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	DTIL Precision BioSciences	Downgrades: Market Perform	n/a	$4.30	-	1	Jun 9, 2022
	NTLA Intellia Therapeutics	Initiates: Outperform	n/a	$9.56	-	1	Feb 18, 2022
	ASMB Assembly Biosciences	Downgrades: Market Perform	n/a	$17.21	-	1	Sep 2, 2021
	VERV Verve Therapeutics	Initiates: Outperform	$92	$11.30	+714.16%	1	Jul 12, 2021
	TSHA Taysha Gene Therapies	Initiates: Outperform	$46	$2.38	+1,832.77%	1	Feb 24, 2021
	GBIO Generation Bio Co.	Initiates: Outperform	$45	$0.30	+14,880.03%	1	Feb 24, 2021
	CRSP CRISPR Therapeutics AG	Initiates: Market Perform	n/a	$47.49	-	1	Mar 14, 2019
	BOLD Boundless Bio	Downgrades: Market Perform	n/a	$1.01	-	2	Nov 7, 2018
	PTCT PTC Therapeutics	Upgrades: Outperform	n/a	$49.84	-	2	Jun 18, 2018

Precision BioSciences

Jun 9, 2022

Downgrades: Market Perform

Price Target: n/a

Current: $4.30

Upside: -

Intellia Therapeutics

Feb 18, 2022

Initiates: Outperform

Price Target: n/a

Current: $9.56

Upside: -

Assembly Biosciences

Sep 2, 2021

Downgrades: Market Perform

Price Target: n/a

Current: $17.21

Upside: -

Verve Therapeutics

Jul 12, 2021

Initiates: Outperform

Price Target: $92

Current: $11.30

Upside: +714.16%

Taysha Gene Therapies

Feb 24, 2021

Initiates: Outperform

Price Target: $46

Current: $2.38

Upside: +1,832.77%

Generation Bio Co.

Feb 24, 2021

Initiates: Outperform

Price Target: $45

Current: $0.30

Upside: +14,880.03%

CRISPR Therapeutics AG

Mar 14, 2019

Initiates: Market Perform

Price Target: n/a

Current: $47.49

Upside: -

Boundless Bio

Nov 7, 2018

Downgrades: Market Perform

Price Target: n/a

Current: $1.01

Upside: -

PTC Therapeutics

Jun 18, 2018

Upgrades: Outperform

Price Target: n/a

Current: $49.84

Upside: -